Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.33 |
| ▸ | BCR | P11274 | 4/20 | 0.33 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ASPH | Q12797 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100850 | 0.91 | CBLB (0.36) | ABL1BCRJUNNFKB1NFKB2 | |
| SCHEMBL6098638 | 0.88 | ASPH (0.33) | ASPHPDE2AHCRTR1 | |
| SCHEMBL6099222 | 0.86 | TAS1R3 (0.35) | ASPHPDE2AHCRTR1GRM4RAF1 | |
| SCHEMBL6097551 | 0.85 | CHRNB2 (0.34) | CNR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6100054 | 0.84 | CHRNB2 (0.35) | CNR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6099397 | 0.83 | CHRNB2 (0.34) | CNR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6098752 | 0.82 | CHRNB2 (0.35) | CNR2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6098194 | 0.81 | XPO1 (0.35) | PDE2AFLT3 | |
| SCHEMBL843512 | 0.81 | CHRNA7 (0.33) | — | |
| SCHEMBL6098747 | 0.80 | TAS1R3 (0.36) | CNR2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | ABL1 236/4885BCR 225/4885JUN 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.